Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically significant and clinically meaningful ...

WILMINGTON, Del., June 02, 2025--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

Among 494 patients who had undergone randomization, overall survival was significantly longer with trastuzumab deruxtecan than with ramucirumab plus paclitaxel (median, 14.7 vs. 11.4 months ...

ENHERTU is also being studied in several ongoing breast cancer trials including the DESTINY-Breast05 Phase III trial which is evaluating ENHERTU in the high-risk adjuvant early HER2-positive setting.

WILMINGTON, Del., May 07, 2025--Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and ...

The DESTINY-Breast11 trial (ClinicalTrials.gov Identifier: NCT05113251) evaluated the efficacy and safety of trastuzumab deruxtecan as a neoadjuvant therapy in 927 participants aged 18 years and ...

In the DESTINY-Breast06 trial, trastuzumab deruxtecan demonstrated a 36% reduction in the risk of disease progression or death compared with chemotherapy (HR, 0.64; 95% CI, 0.54-0.76; P < .0001 ...

Trastuzumab Deruxtecan in Metastatic Breast Cancer Results Of the 866 patients who underwent randomization, 713 had HER2-low disease, and 153 had HER2-ultralow disease.

Summary The DESTINY-Breast12 trial revealed that trastuzumab deruxtecan (T-DXd) effectively targets brain metastases in HER2-positive breast cancer. With a median progression-free survival of 17.3 ...

Background: Trastuzumab deruxtecan (TDXd), an antibody drug conjugate, was first approved in the UK for the treatment of human epidermal growth factor receptor 2 positive (HER2+) metastatic breast ...